Transforming growth factor beta and progression of renal disease

Phyllis August, Manikkam Suthanthiran

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

End-stage renal disease (ESRD) is more frequent in African Americans compared to whites. Many factors may be responsible, including genetic differences, increased prevalence of risk factors, and socioeconomic factors; however, to date, these proposed genetic or environmental factors have not provided a satisfactory explanation for the increased risk of ESRD in African Americans. Because renal fibrosis is a correlate of progressive renal failure and a dominant feature of ESRD, and because transforming growth factor beta 1 (TGF-β1) can induce fibrosis and renal insufficiency, we explored the hypothesis that TGF-β1 hyperexpression is more frequent in African Americans compared to whites. We tested our hypotheses by measuring TGF-β1 levels in African Americans and white patients with ESRD, hypertension, and in normal patients. In hypertensive and normal patients, we also evaluated TGF-β1 mRNA levels, and TGF-β1 DNA polymorphisms. We demonstrated that circulating levels of TGF-β1 are higher in African American ESRD patients, hypertensive patients, and normal control patients compared to their white counterparts. We also reported that TGF-β1 mRNA levels are higher in hypertensives compared to normotensives. Our preliminary genetic analyses suggest that TGF-β1 DNA polymorphisms may distinguish hypertensives from normotensives, and our laboratory is currently investigating racial differences in TGF-β1 DNA polymorphisms. Our observations of hyperexpression of TGF-β1 in African Americans suggest a mechanism for the increased prevalence of renal failure and hypertensive target organ damage in this population.

Original languageEnglish
JournalKidney International, Supplement
Volume64
Issue number87
Publication statusPublished - 1 Nov 2003
Externally publishedYes

Fingerprint

Transforming Growth Factor beta
Disease Progression
Kidney
African Americans
Chronic Kidney Failure
Renal Insufficiency
DNA
Fibrosis
Messenger RNA
Renal Hypertension

Keywords

  • Hypertension
  • Renal disease
  • TGF-β

ASJC Scopus subject areas

  • Nephrology

Cite this

Transforming growth factor beta and progression of renal disease. / August, Phyllis; Suthanthiran, Manikkam.

In: Kidney International, Supplement, Vol. 64, No. 87, 01.11.2003.

Research output: Contribution to journalArticle

@article{f2c180d739bc449b94f074d68e157d53,
title = "Transforming growth factor beta and progression of renal disease",
abstract = "End-stage renal disease (ESRD) is more frequent in African Americans compared to whites. Many factors may be responsible, including genetic differences, increased prevalence of risk factors, and socioeconomic factors; however, to date, these proposed genetic or environmental factors have not provided a satisfactory explanation for the increased risk of ESRD in African Americans. Because renal fibrosis is a correlate of progressive renal failure and a dominant feature of ESRD, and because transforming growth factor beta 1 (TGF-β1) can induce fibrosis and renal insufficiency, we explored the hypothesis that TGF-β1 hyperexpression is more frequent in African Americans compared to whites. We tested our hypotheses by measuring TGF-β1 levels in African Americans and white patients with ESRD, hypertension, and in normal patients. In hypertensive and normal patients, we also evaluated TGF-β1 mRNA levels, and TGF-β1 DNA polymorphisms. We demonstrated that circulating levels of TGF-β1 are higher in African American ESRD patients, hypertensive patients, and normal control patients compared to their white counterparts. We also reported that TGF-β1 mRNA levels are higher in hypertensives compared to normotensives. Our preliminary genetic analyses suggest that TGF-β1 DNA polymorphisms may distinguish hypertensives from normotensives, and our laboratory is currently investigating racial differences in TGF-β1 DNA polymorphisms. Our observations of hyperexpression of TGF-β1 in African Americans suggest a mechanism for the increased prevalence of renal failure and hypertensive target organ damage in this population.",
keywords = "Hypertension, Renal disease, TGF-β",
author = "Phyllis August and Manikkam Suthanthiran",
year = "2003",
month = "11",
day = "1",
language = "English",
volume = "64",
journal = "Kidney International, Supplement",
issn = "0098-6577",
publisher = "Wiley-Blackwell",
number = "87",

}

TY - JOUR

T1 - Transforming growth factor beta and progression of renal disease

AU - August, Phyllis

AU - Suthanthiran, Manikkam

PY - 2003/11/1

Y1 - 2003/11/1

N2 - End-stage renal disease (ESRD) is more frequent in African Americans compared to whites. Many factors may be responsible, including genetic differences, increased prevalence of risk factors, and socioeconomic factors; however, to date, these proposed genetic or environmental factors have not provided a satisfactory explanation for the increased risk of ESRD in African Americans. Because renal fibrosis is a correlate of progressive renal failure and a dominant feature of ESRD, and because transforming growth factor beta 1 (TGF-β1) can induce fibrosis and renal insufficiency, we explored the hypothesis that TGF-β1 hyperexpression is more frequent in African Americans compared to whites. We tested our hypotheses by measuring TGF-β1 levels in African Americans and white patients with ESRD, hypertension, and in normal patients. In hypertensive and normal patients, we also evaluated TGF-β1 mRNA levels, and TGF-β1 DNA polymorphisms. We demonstrated that circulating levels of TGF-β1 are higher in African American ESRD patients, hypertensive patients, and normal control patients compared to their white counterparts. We also reported that TGF-β1 mRNA levels are higher in hypertensives compared to normotensives. Our preliminary genetic analyses suggest that TGF-β1 DNA polymorphisms may distinguish hypertensives from normotensives, and our laboratory is currently investigating racial differences in TGF-β1 DNA polymorphisms. Our observations of hyperexpression of TGF-β1 in African Americans suggest a mechanism for the increased prevalence of renal failure and hypertensive target organ damage in this population.

AB - End-stage renal disease (ESRD) is more frequent in African Americans compared to whites. Many factors may be responsible, including genetic differences, increased prevalence of risk factors, and socioeconomic factors; however, to date, these proposed genetic or environmental factors have not provided a satisfactory explanation for the increased risk of ESRD in African Americans. Because renal fibrosis is a correlate of progressive renal failure and a dominant feature of ESRD, and because transforming growth factor beta 1 (TGF-β1) can induce fibrosis and renal insufficiency, we explored the hypothesis that TGF-β1 hyperexpression is more frequent in African Americans compared to whites. We tested our hypotheses by measuring TGF-β1 levels in African Americans and white patients with ESRD, hypertension, and in normal patients. In hypertensive and normal patients, we also evaluated TGF-β1 mRNA levels, and TGF-β1 DNA polymorphisms. We demonstrated that circulating levels of TGF-β1 are higher in African American ESRD patients, hypertensive patients, and normal control patients compared to their white counterparts. We also reported that TGF-β1 mRNA levels are higher in hypertensives compared to normotensives. Our preliminary genetic analyses suggest that TGF-β1 DNA polymorphisms may distinguish hypertensives from normotensives, and our laboratory is currently investigating racial differences in TGF-β1 DNA polymorphisms. Our observations of hyperexpression of TGF-β1 in African Americans suggest a mechanism for the increased prevalence of renal failure and hypertensive target organ damage in this population.

KW - Hypertension

KW - Renal disease

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=0142169489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142169489&partnerID=8YFLogxK

M3 - Article

C2 - 14531781

AN - SCOPUS:0142169489

VL - 64

JO - Kidney International, Supplement

JF - Kidney International, Supplement

SN - 0098-6577

IS - 87

ER -